Insulin News and Research RSS Feed - Insulin News and Research

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.
Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

Three Johns Hopkins University School of Medicine researchers have been awarded two-year grants for their work on potential treatments for diabetes, Novo Nordisk announced this month. Of the 110 initial submissions to the new Novo Nordisk Diabetes and Obesity Biologics Science Forum Program, only four projects were funded, three of which are led by Johns Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., Ph.D. [More]

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure. [More]

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
Protein expression predicts postop NSCLC recurrence, survival

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer. [More]
Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

It’s been over a decade since the first Diabetes Attitudes Wishes and Needs (DAWN) study showed that psychosocial aspects of diabetes pose specific challenges and barriers to optimal glycaemic control for people living with diabetes. [More]
Scientists solve a decades-long mystery of cell biology

Scientists solve a decades-long mystery of cell biology

A team led by scientists at The Scripps Research Institute has identified a long-sought protein that facilitates one of the most basic functions of cells: regulating their volume to keep from swelling excessively. [More]

Experts connect sleep deprivation to elevated risk of developing diabetes

Excessive noise is a common cause for a loss of sleep. Now, experts connect sleep deprivation to an elevated risk of developing diabetes. [More]
IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

​In the study published today in the Journal of Clinical Investigation (JCI), one of the journals with highest impact in experimental medicine, the researchers associate the activity of the DOR protein with muscle atrophy and point to DOR as a plausible target against which to develop a drug to prevent muscle deterioration in certain diseases. [More]

Gerresheimer’s revenues increase EUR 297.5M to 0.3% in first quarter 2014

Gerresheimer AG, one of the leading partners to the pharma and healthcare industry worldwide, began financial year 2014 with a solid start."I am satisfied with our performance in the first quarter of 2014. [More]
Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Adocia announces positive results from BioChaperone Lispro phase IIa clinical trial

Adocia announces positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog commercial insulin. Adocia’s formulation incorporates proprietary BioChaperone technology which enables accelerated absorption of prandial insulins. Humalog, which is now off-patent, has annual sales of USD 2.6 billion. [More]
Novel discovery could lead to new therapy to combat obesity, diabetes

Novel discovery could lead to new therapy to combat obesity, diabetes

By manipulating a biochemical process that underlies cells' energy-burning abilities, investigators at Beth Israel Deaconess Medical Center have made a novel discovery that could lead to a new therapy to combat obesity and diabetes. [More]
LabStyle Innovations, FatSecret partner for Dario Diabetes Management Solution

LabStyle Innovations, FatSecret partner for Dario Diabetes Management Solution

LabStyle Innovations Corp., developer of the Dario Diabetes Management Solution, today announced a partnership with the world's leading global nutrition data application, FatSecret. [More]
Researchers identify novel compound effective against drug-resistant lung cancer

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective. [More]

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes. [More]

MicroBiome Therapeutics to present clinical trial data of NM504 in type 2 diabetes, prediabetes at ICE/ENDO 2014

MicroBiome Therapeutics LLC, today announced that data from the company's clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society. [More]

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. [More]

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects. [More]

Adolescents in Sweden are at increased risk for type 1 diabetes than previously thought

New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) suggests that Sweden-the country already thought to have the second highest prevalence of type 1 diabetes in the world-could have 2-3 times more adolescents and young adults with type 1 diabetes than previously estimated. [More]

Magnetically controlled nanoparticles force tumour cells to 'self-destruct', shows research

Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden. [More]

Thorne Research launches NiaCel that supports endurance, energy and healthy aging

Thorne Research today announced the launch of NiaCel™, an innovative nutritional supplement that supports endurance, energy, and healthy aging. [More]